Editorial: Infliximab induction therapy in paediatric Crohn's disease — A cost‐effective strategy? Authors' reply
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.18053 ↗At a glance
Editorial in Alimentary Pharmacology & Therapeutics, 2024. Written by Stephanie A Vuijk and 1 co-authors. Institution: Department of Paediatric Gastroenterology, Erasmus Medical Center/Sophia Children's Hospital, Rotterdam, The Netherlands. Major MEDLINE topics: Crohn Disease, Infliximab, Cost-Benefit Analysis, Gastrointestinal Agents. 10 references.
Abstract (original language)
LINKED CONTENT This article is linked to Vuijk et al papers. To view these articles, visit https://doi.org/10.1111/apt.18000 and https://doi.org/10.1111/apt.18033
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Paediatric Gastroenterology, Erasmus Medical Center/Sophia Children's Hospital, Rotterdam, The Netherlands.
ORCID profiles: Stephanie A Vuijk, Lissy de Ridder
Cite
APA
Vuijk, S. A., & de Ridder, L. (2024). Editorial: Infliximab induction therapy in paediatric Crohn's disease — A cost‐effective strategy? Authors' reply. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18053
Vancouver
Vuijk SA, de Ridder L. Editorial: Infliximab induction therapy in paediatric Crohn's disease — A cost‐effective strategy? Authors' reply. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18053
BibTeX
@article{Vuijk2024,
author = {Vuijk, Stephanie A and de Ridder, Lissy},
title = {Editorial: Infliximab induction therapy in paediatric Crohn's disease — A cost‐effective strategy? Authors' reply},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.18053}
}
EUVIMED